Evaluation of New Tuberculosis Diagnostic Tests and Interventions in Indonesia to Increase Case Notifications
Led by Universitas Padjadjaran · Updated on 2026-09-25
40000
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether a new non-sputum-based diagnostic test and other related interventions can increase tuberculosis TB case notifications and improve TB diagnosis in healthcare facilities in Indonesia. This cluster-randomised controlled trial compares a diagnostic intervention package delivered in healthcare facilities and communities with the standard of care. The study is part of a larger project addressing delays and challenges in TB diagnosis, especially in low-resource settings where many patients cannot produce sputum samples needed for traditional tests.
The intervention package includes introducing a new near point-of-care nPOC TB test, optimizing clinical algorithms to incorporate this test, promotional activities to increase patient attendance and test use in clinics and pharmacies, and household contact investigations supported by community health volunteers. Healthcare facilities in the intervention arm receive this multi-component package, while those in the control arm continue standard care but receive refresher training on TB case notification.
Participants will be involved over a follow-up period of 12 months after the intervention roll-out, with TB case notifications and other outcomes measured from national TB information systems. Additional sub-studies will assess patient pathways, costs, provider testing behavior, and health system diagnostic costs. Outcomes include changes in TB case notifications, diagnostic confirmation rates, time to diagnosis, healthcare visits before diagnosis, and costs related to TB diagnosis in both healthcare and community settings.
CONDITIONS
Brief Title
Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia
Research Team
E
EVIDENT Study Contact Centre
N
Nur Afifah, MD, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Aged between more than 28 days and 14 years old with cough lasting 2 weeks or more, acute malnutrition, or recent weight loss after TB contact in the past year
Aged 15 years or older with cough lasting 2 weeks or more or bloody cough, with or without symptoms like fever, weight loss, night sweat, fatigue, chest pain, breathlessness, loss of appetite, or shivering
You will not qualify if you...
Have started tuberculosis treatment or tuberculosis preventive therapy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Intervention or Standard Care
Duration - 12 months
Participants receive either the new diagnostic intervention package including the near point-of-care TB test, clinical algorithm updates, promotion, and household contact investigations, or continue with standard care while healthcare providers receive refresher training on TB notification.
Visits occur as part of routine healthcare and community activities
Follow-up and Outcome Assessment
Duration - 12 months
Participants' TB case notifications and related outcomes are monitored for 12 months after the intervention roll-out using national TB information systems and additional sub-studies.
Data collection and assessments occur during this period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Testing a 1-Month Ultra-Short Treatment to Prevent Active Tuberculosis in School Contacts
Comparing 1H3P3 and 3HR Regimens in Adolescents and School Staff
Phase 2b Study Comparing JDB0131 Benzenesulfonate Tablets and Delamanid
in Combination Treatments for Rifampin-Resistant Tuberculosis
Safety and Drug Level Study of Isoniazid Inhalation by Wet Nebulization in Adults with Tuberculosis
Dose Finding and Safety Study of Daily Rifapentine with Isoniazid for Tuberculosis Prevention in Children Under 13 With and Without HIV
Phase 2 Open-label Study of Oral Alpibectir with Ethionamide and with Rifampicin, Pyrazinamide, and Ethambutol in Adults with Newly Diagnosed Drug-Susceptible Pulmonary Tuberculosis
Phase 1 Study of Oral Microgynon and Ganfeborole Interaction in Healthy Non-Childbearing Female Adults Aged 18 to 64 Years
Screening for Tuberculosis in High-Risk Groups Living in Barcelona
Study on Screening for Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Comparing Moderate Drinking Advice to Abstention Advice for Adults 50 to 75 Years to Prevent Major Diseases and Death
Supporting and Accelerating Tuberculosis Research Through Assessment of New Point-of-Care Diagnostic Tests
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
New Manual Quantitative Polymerase Chain Reaction Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That Rivals Sputum-based Molecular Tuberculosis Diagnostics.